RecruitingNot Applicable

Modifying PEST for Psoriatic Arthritis Screening

Canada502 participantsStarted 2025-01-23

Plain-language summary

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
✓. Adult patients at the time of informed consent signature
✓. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
✓. Residents of Canada

Exclusion criteria

✕. Patients who have previously screened positive for PsA through PEST.
✕. Patients who have been diagnosed with PsA.
✕. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
✕. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.

What they're measuring

Positive Predictive Value (PPV) for PEST and PEST+2 in adult patients with moderate-to-severe plaque PsO who are candidates for bDMARDs

Timeframe: Up to approximately 1 year

Trial details

NCT IDNCT06382051

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-08-28

Contact for this trial

Novartis Pharmaceuticals

+41613241111 novartis.email@novartis.com

View on ClinicalTrials.gov More Plaque Psoriasis trials